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Abstract
The magnitude and consequences of prescription opioid (PO) misuse and harms (including rising demand for PO
disorder treatment) in Canada have been well-documented. Despite a limited evidence-base for PO dependence
treatment, opioid maintenance therapy (OMT) - mostly by means of methadone maintenance treatment (MMT) - has
become the de facto first-line treatment for PO-disorders. For example in the most populous province of Ontario, some
50,000 patients - large proportions of them young adults - are enrolled in MMT, resulting in a MMT-rate that is 3–4
times higher than that of the United States. MMT in Ontario has widely proliferated towards a quasi-treatment industry
within a system context of the public fee-payer offering generous incentives for community-based MMT providers.
Contrary to the proliferation of MMT, there has been no commensurate increase in availability of alternative (e.g., detox,
tapering, behavioral), and less intrusive and/or costly, treatments which may provide therapeutic benefits at least for
sub-sets of PO-dependent patients. Given the extensive PO-dependence burden combined with its distinct socio-
demographic and clinical profile (e.g., involving many young people, less intensive or risky opioid use), an evidence-based
‘stepped-care’ model for PO dependence treatment ought to be developed in Canada where MMT constitutes one, but
likely a last resort or option, for treatment. Other, less intrusive treatment options as well as the best mix of treatment
options should be systematically investigated and implemented. This case study has relevance and implications for
evidence-based treatment also for the increasing number of other jurisdictions where PO misuse and disorders have
been rising.
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By now, the detrimental extent and consequences of the
‘epidemic’ of prescription opioid (PO) misuse and harms in
North America are well documented. Despite recent ‘plat-
eauing’ effects, some 4.2 % of adults report non-medical
PO use (NMPOU) and some 17,000 PO-related poisoning
fatalities occur annually in the United States [1–4]. In
Canada, NMPOU prevalence continues to be second only
to cannabis among adults and adolescents when compared
to illicit drug use. While PO-related poisoning deaths have
shifted somewhat between different PO formulations (e.g.,
oxycodone to hydromorphone or fentanyl) their overall
numbers continue to climb and are proportionally similar
to those recorded in the US [5–7]. Ample evidence has also
shown that the high levels of PO dispensing are the
principal driver of the corresponding levels of PO-related
harms in North America [1, 8, 9].
A related but commonly overlooked phenomenon con-
cerns the realities of treatment for PO-related disorders. A
recent report in the Lancet (2012) concluded that “re-
search into the treatment for [PO] addiction has been
chronically neglected. As a result, the evidence base that
informs best practice is thin […] The ‘standard treatment’
for [PO] dependence is evolving, and [there is no] single
current standard at this time” [10]. Yet, current Canadian
treatment system realities seem to suggest the opposite. In
Ontario, Canada’s most populous province (~13.6 million
pop.), the number of individuals enrolled in methadone
maintenance treatment (MMT) has skyrocketed to just
under 50,000 in 2014 (from a mere 3000 in 1996, and
29,000 in 2010), with the vast majority of recent enroll-
ments presumed to be PO-related. This situation is in com-
parison to the United States (US), where there is a similar
prevalence of opioid misuse, with opioid maintenance
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treatment (OMT) being the mainstay similar in design
and delivery modes to Canada [11–13]. In the US, how-
ever, the total number of OMT clients has increased from
some 230,000 (2003) to 340,000 in 2011 - an increase of
about 50 % yet making for an OMT enrollment rate that
is only about 25–30 % that of Ontario [14]. Importantly,
while the number of MMT enrolments in Ontario con-
tinues to rise, 29 % of MMT patients (in 2014) were
<30 years - and up to 1 in 5 were <25 years in some health
regions. MMT patients in this age range likely had rela-
tively short or only tangential involvement with PO mis-
use prior to treatment, yet likely will be involved in MMT
for long periods of time given the lifelong nature of this
treatment for many patients [15, 16]. Further, PO disorder
patients are commonly more socio-economically integrated
and feature lower clinical risk profiles (e.g., less severe ad-
diction severity, less injecting and/or co-morbidities) than
the profiles of (largely heroin using) patients that entered
OMT pre-2000. Notably, the application of the new DSM-
V criteria for PO-disorders is expected to further consider-
ably increase the number of people initiated on OMT [17].
The above data reflect that OMT - mostly with metha-
done but some suboxone-based in exceptional cases - has
proliferated as the de facto first-line treatment for PO-
related disorders in Ontario. This is despite the fact that
OMT is designed as long-term - in many cases for life -
pharmacotherapy for most patients [18]. The predominant
reliance on OMT for PO-disorder treatment is mainly
based by research evidence from long-term heroin users,
even though substantial, clinically relevant differences
between heroin and PO users are documented [19–23].
Furthermore, this practice has evolved largely in the ab-
sence of an evidence-based stepped-treatment model for
PO-disorders, even though evidence exists for benefits of
treatment options less intrusive (and potentially less
costly) than MMT. For example, several studies - including
youth/adolescent patient samples - have shown good select
effectiveness involving (buprenorphine-naloxone or naltrex-
one) medication-supported taper treatments for PO-
dependence (with up to 50 % of good treatment outcomes
at 3- to 6-months follow-up points) from which many pa-
tients would likely benefit [24–27]. Behavioral treatments
have both shown some effectiveness as singular treatment
interventions as well as in combination with medication-
supported detoxification for opioid disorders yet remain
under-explored [28–31]. Notably, there neither are any
Canadian research studies systematically examining, nor
are treatment guidelines universally integrating these alter-
native treatment modalities for PO-disorders despite the
acute and expanding severity of this problem.
While the pharmaceutical industry’s corporate greed
and tactics have been popularly blamed - and legally
punished - for the PO abuse epidemic (e.g., [32, 33]),
economics within the health care system appear to exert
an un-desirable dynamic in the realities of treatment for
PO disorders. In addition to standard reimbursement for
OMT care within Ontario’s public fee-for-service-based
health care system, the province introduced additional
financial ‘incentives’ in 2011 to entice more community
physicians and pharmacies into MMT delivery [34, 35].
In this context, an extensive proliferation of numerous ‘for-
profit’ MMT-only clinics occurred focussing on economies-
of-scale - i.e., large patient numbers - yet also featuring
treatment quality problems (e.g., compromised patient care,
inappropriate take-homes or “carries”, excessive urine test-
ing) [36–38]. While the MMT-focussed incentives have cre-
ated a proliferation of MMTclinics and patients in Ontario,
there has been no commensurate investment in short- or
mid-term treatment interventions, for example with abstin-
ence, where possible, as a main goal for potentially suitable
patient sub-groups. While these treatment interventions
may potentially be more care effort- or management-
intensive in the acute treatment phase, they be less costly
for the system - yet also provide less income for OMT pro-
viders or medications producers - in the long run. To illus-
trate: The current annual public expenditures - or
reimbursement fees - for MMT alone in Ontario are esti-
mated to exceed $250,000,000 [39].
Allow us to be perfectly clear: Our position is not ‘anti’-
OMT for PO-disorders. In fact, several of the present au-
thors have actively argued for the expansion of OMT
availability in Canada when this was still a highly re-
stricted and scarce treatment for the treatment of opioid
disorders not so long ago [15, 40]. We believe however
that OMT’s proliferation as the first-line-treatment for PO
disorders has been propelled to excess by several of the
wrong reasons and that an evidence-based stepped-care
model - including non-pharmacotherapy/-maintenance
components for initial treatment steps - is urgently re-
quired to provide a best and most patient-oriented treat-
ment approaches on a system level. Stepped-care models
have been promoted and/or implemented for other areas
of mental health or substance abuse (e.g., alcohol or nico-
tine dependence) treatment [41–44]. In essence, what a
stepped care model attempts to do is to align treatment
from different options, and treatment intensity, based on
key characteristics - e.g., based on comprehensive assess-
ment information - that predict patient need, with an
overall goal of employing least intensive but most promis-
ing treatment on a case-to-case basis. In the specific con-
text of PO disorders, basic treatment options could, for
example, include: brief/cognitive-behavioral interventions;
medications-supported (short-term) detoxification/taper-
ing; opioid maintenance treatment. If patients do not re-
spond well to their initially assigned treatment, they
would be stepped up to more intensive treatment options.
Unquestionably, there are a large number of individ-
uals suffering from PO disorders in Canada who require
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treatment. While OMT undoubtedly brings therapeutic
benefits to many opioid-dependent people, and is the
best available therapuetic choice for a large sub-group of
patients with PO disorder it also implies the continued
exposure of patients to potential correlated adverse ef-
fects (e.g., brain structure changes, depression, mortality)
of chronic opioid intake - risks that should be minimized
especially with young and non-severely dependent pa-
tients [45–50]. Long-term OMT should thus surely be
an available treatment option in a continuum-of-care,
but primarily for non-responders to less intrusive alter-
natives where these seem reasonably indicated as a first
treatment option. In order to implement a stepped-care
model for PO disorder treatment in Canada, compre-
hensive research needs to be conducted, including
both on the socio-clinical characteristics of patients
predicting success in the different categories of treat-
ment options, as well as the best mix of varying - in-
cluding non-maintenance - treatment options in a
comprehensive stepped-care approach and system. In
this context, we also noted with curiosity that the
‘Executive Committee’ of Canada’s ‘Prescription Drug
Strategy’ included a senior representative of Reckitt-
Benckiser, the then pharmaceutical company manufac-
turing a principal OMT product (Suboxone) approved
in Canada, and has been formally lobbying the
Minister of Health for regulatory practice changes in
explicit reference to opioid products from other
pharmaceutical opioid manufacturers in this role [51].
This mixes competing interests too closely, and would
not be acceptable in other comparable arenas of
health care policy (see, for example, [52, 53]).
In summary, we urge policy-makers at relevant levels
in Canada to both facilitate the development of an
evidence-base - building on existent and facilitate the
generation of new data required - for effective non-
OMT options towards a comprehensive overall
continuum-of-care for PO disorder treatment with
OMT as a ‘last resort’; related, we urge the correction of
the predominant economic parameters in opioid dis-
order treatment that seem to have unduly influenced the
recent excessive expansions of OMT in Ontario, towards
a more and overall public health oriented approach to
treatment and care. As the burdensome issue of PO mis-
use and disorders is increasing in other national system
contexts [54, 55], the lessons from Canada may provide
useful guidance for the development or shaping of treat-
ment options and systems there as well.
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